How the SYNJ2 protein helps move RNA and keep brain cell mitochondria healthy
Investigating the Role of Neuronal SYNJ2 in mRNA Transport and Mitochondrial Function
Researchers are looking at whether the SYNJ2 protein helps nerve cells maintain their energy-producing mitochondria, which could matter to people with Alzheimer's and related brain diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11285176 on NIH RePORTER |
What this research studies
This work looks at how SYNJ2 tethers specific mRNA, including the message for the mitochondrial protein PINK1, to mitochondria so proteins can be made near the far ends of nerve cells. In the lab, scientists will use cultured neurons and molecular imaging to track mRNA and mitochondria movement, alter SYNJ2 levels, and measure mitochondrial health and neuron function. They will test how disrupting this transport affects neuron survival and the ability of mitochondria to produce energy. Results will help explain whether restoring local mRNA transport could protect neurons in diseases like Alzheimer’s or Parkinson’s.
Who could benefit from this research
Good fit: People with Alzheimer's disease or those with genetic forms of Parkinson's (such as PINK1 mutations), especially in early stages, would be the most relevant patient groups if related human studies are developed.
Not a fit: Patients with very advanced disease or cognitive decline from unrelated causes may be less likely to receive direct benefits from this basic laboratory research in the short term.
Why it matters
Potential benefit: If successful, this research could point to new ways to protect nerve cell energy systems and slow neurodegeneration in Alzheimer’s and related disorders.
How similar studies have performed: This builds on emerging laboratory findings about mRNA transport to mitochondria, but translating these mechanisms into therapies remains largely unproven.
Where this research is happening
New York, United States
- New York University — New York, United States (Active)
Researchers
- Principal investigator: Gibbs, Whitney Sharee — New York University
- Study coordinator: Gibbs, Whitney Sharee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.